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INTRODUCTION
Gastric cancer (GC) is one of the most common mali gnancies with high morbidity and mortality worldwide [1] . Adequate surgical resection is the only curative therapeutic option for GC. In East Asia, gastrectomy with D2 lymphadenectomy is the standard surgical treatment [2, 3] . In fact, based on the results of the Dutch D1D2 trial [4] , the European and United States guidelines have likewise recommended the procedure [5, 6] . However, even with a potentially curative resection, approximately 50% of patients develop recurrence within 5 years after surgery [7, 8] , and 50%90% of patients die of tumor relapses [9] . To decrease the risk of postoperative recurrence, various regimens for adjuvant chemotherapy have been implemented over the past 40 years. Results of two large randomized phase 3 trials, which are the ACTSGC and CLASSIC trials, have shown survival benefit from adjuvant chemotherapy in patients who underwent D2 radical resection for stage ⅡⅢ disease [7, 8] . In the ACTSGC study, intake of S1 treatment for one year after D2 gastrectomy increased the five-year relapsefree survival (RFS) and overall survival (OS) by 12.3% and 10.6%, respectively [7] . In CLASSIC trial, 6 mo of capecitabine plus oxaliplatin (XELOX) therapy improved the estimated fiveyear diseasefree survival (DFS) and OS by 15% and 9%, respectively [8] .
To date, only the two adjuvant chemotherapy regimens mentioned above have been proven to be significantly efficient in stage ⅡⅢ GC patients who underwent D2 dissection. However, some aspects in the previous two studies on adjuvant chemotherapy need to be improved. In the ACTSGC trial, patients had a low compliance (65.8%) in taking S1 for one year and a subgroup analysis showed that the effect was insufficient in the elderly or stage Ⅲ patients [7] . In the CLASSIC study, patients also had a low treatment completion rate (67%) [8] . Therefore, new adjuvant chemotherapy regimens need to be explored.
Considering that both S1 monotherapy and combination therapy with oxaliplatin plus capecitabine have become the standard treatment for GC patients after D2 gastrectomy, a phase 2, singlearm study that investigated the safety of adjuvant chemotherapy regimen with S1 plus oxaliplatin (SOX) in Japanese patients showed better toxicity profiles and relatively high completion rate (74.2%) [10] . Therefore, adjuvant chemotherapy with SOX for GC is most likely reasonable and efficacious. Based on the aforementioned, we conducted this multicenter retrospective study to evaluate the safety and efficacy of SOX as adjuvant chemotherapy in stage ⅠBⅢC GC after D2 gastrectomy.
MATERIALS AND METHODS

Study population
The study included GC patients who underwent D2 gastrectomy at the Affiliated Hospital of Qinghai University, People's Hospital of Qinghai Province, Qinghai Red Cross Hospital, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences from September 2009 to December 2011. Patients were selected if they met the following eligibility criteria: (1) histologically confirmed adenocarcinoma of the stomach; and (2) stage ⅠB (pT1N1M0) or ⅠB (pT2N0M0) with highrisk features including poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or < 50 years of age, stage Ⅱ, or Ⅲ disease according to the Seventh Edition of the American Joint Committee on Cancer (AJCC) classification. The following patients were excluded: (1) stage ⅠA or ⅠB (pT2N0M0) disease without aforementioned highrisk features; (2) those who received radiotherapy before or after surgery; (3) those who received neoadjuvant chemotherapy; and (4) those who received adjuvant chemotherapy except for SOX or XELOX regimens.
We analyzed the clinicopathologic characteristics of the enrolled patients, including age, sex, tumor location, tumor grade, pTNM stage (based on the Seventh AJCC classification), lymphatic and venous invasion, and perineural invasion. All eligible patients were divided into three parts, patients who treated with surgery alone, patients who received postoperative SOX adjuvant chemotherapy, and those who received XELOX adjuvant chemotherapy.
The study was approved by the institutional review boards of the Affiliated Hospital of Qinghai University, People's Hospital of Qinghai Province, Qinghai Red Cross Hospital, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Adjuvant chemotherapy regimens
SOX adjuvant chemotherapy was started within 36 wk after D2 gastrectomy. In all 3wk cycles, S1 was given orally twice daily for 2 wk at a dose of 80 mg/d for patients with a body surface area (BSA) < 
Postoperative follow-up
Patients in the surgery alone group did not receive any antineoplastic agent until there was a confirmed recurrence. All the enrolled patients underwent he matologic tests, physical examination, and computed tomography every three months for the first two years after surgery, every six months from the third year to the fifth year, and annually thereafter. Data, including tumor relapse, death from any cause and the last followup date were collected. DFS was defined as the time from surgery to tumor recurrence or the last follow-up date. OS was defined as the time from surgery to death or the last followup date.
Statistical analysis
To compare the baseline clinicopathologic characteristics between the adjuvant SOX and the surgery alone groups, the adjuvant SOX and the adjuvant XELOX groups, the χ 2 test or Fisher's exact test was used for categorical variables, whereas the MannWhitney U test was used for continuous variables. Survival outcomes were estimated using the KaplanMeier method, and the differences in survival between the treatment groups were compared using the logrank test. An unadjusted Cox proportional hazards model was used to calculate the hazard ratio (HR) with the 95% confidence interval (CI) for the survival outcomes in all groups. To determine the independent prognostic factors for OS, a multiple regression analysis using a Cox proportional hazards model was performed. All tests were twosided, and P < 0.05 was considered statistically significant.
We used propensity score matching to reduce to the greatest extent the effects of selection bias and the possible confounding factors. Propensity scores were estimated by a logistic regression model of the following covariates: age, sex, tumor location, tumor grade, pTNM stage, lymphatic and venous invasion, and perineural invasion. Patients in the adjuvant SOX group were matched in a 1:2 ration with those in the surgery alone group and 1:1 ration with those in the adjuvant XELOX group using calculated propensity scores with a 0.05 caliper width. And only the patients matched with propensity scores were included in the timetoevent analyses. We performed the propensity score matching using the Matching package in R, version 3.3.1 (R Foundation) [11] . Sensitivity analysis was conducted by adding co morbidity to our propensity score model before repeating the DFS and OS analyses between the adjuvant SOX group and the surgery alone group. Except for the propensity score matching, all statistical analyses were performed using SPSS software version 21.0 (SPSS Inc., Chicago, IL, United States).
RESULTS
Study population
From September 2009 to December 2011, there were 1944 GC patients who were treated by curative gastrectomy with D2 lymphadenectomy. Among them, 1077 patients were excluded for being in stage Ⅰ A or ⅠB (pT2N0M0) without highrisk features (n = 249), having received radiotherapy before or after surgery (n = 105), neoadjuvant chemotherapy (n = 60), other adjuvant chemotherapy except for SOX or XELOX regimens after surgery (n = 663). A total of 867 patients were analyzed in this study; 124 patients received SOX adjuvant chemotherapy, 60 patients received XELOX adjuvant therapy and 683 patients underwent surgery alone. After propensity score matching, 117 pairs of 1:2 matched patients (i.e., 351patients) and 57 pairs of 1:1 matched patients (i.e., 114 patients) were generated ( Figure 1 ).
The clinicopathologic characteristics of patients in adjuvant SOX group and surgery alone group before and after matching are shown in Table 1 . Overall, compared with the surgery alone group, the adjuvant SOX group had more poor to moderate grade tumor (78.23% vs 62.52%), more pathologic stage Ⅲ cancer (70.16% vs 37.19%), and more lymphatic and venous invasion (30.65% vs 16.11%). After matching, all the baseline clinicopathologic characteristics including age, sex, tumor location, tumor grade, pTNM stage, lymphatic and venous invasion, and perineural invasion, were similar between the two groups. The clinicopathologic characteristics of patients in adjuvant SOX group and adjuvant XELOX group before and after matching are shown in Table 2 .
Survival benefit of adjuvant SOX chemotherapy
In adjuvant SOX group, a median cycle of 4 (112 cycles) were received. After a median followup of 42 mo after gastrectomy, the number of patients who developed relapse and died was 42 (35.9%) and 36 (30.8%), respectively, in the adjuvant SOX group and 122 (52.1%) and 117 (50.0%), respectively, in the surgery alone group. The estimated five-year DFS was 57.5% in the adjuvant SOX group and 44.6% in the surgery alone group (HR = 0.559; 95%CI: 0.3930.794; P = 0.001; Figure 2A ). The estimated fiveyear OS was 68.3% in the adjuvant SOX group and 45.8% in the surgery alone group (HR = 0.505; 95%CI: 0.3480.734; P < 0.001; Figure 2B ). After addition of comorbidity to the propensity score model in the sensitivity analysis, 116 pairs of 1:2 matched patients (i.e., 348 patients) were ge nerated. Repeat analyses showed that compared with the surgery alone group, the adjuvant SOX group had significantly better DFS (HR = 0.542; 95%CI: 0.3770.779; P = 0.001) and OS (HR = 0.496; 95%CI: 0.3380.728; P < 0.001).
Subgroup analysis
To further investigate whether stage Ⅲ or elderly patients can benefit from SOX adjuvant chemotherapy, Figure 3A ). The estimated five-year OS rates were 34.1% in the surgery alone group and 62.5% in the adjuvant SOX group, with an HR of 0.458 (95%CI: 0.3020.692; P < 0.001; Figure 3B ).
In patients aged ≤ 60 years, the estimated five year DFS rates were 54.5% in the surgery alone group and 61.6% in the adjuvant SOX group, with an HR of 0.553 (95%CI: 0.3190.959; P = 0.032; Figure 3C ). The estimated five-year OS rates were 55.2% in the surgery alone group and 77.2% in the adjuvant SOX group, with an HR of 0.435 (95%CI: 0.236-0.802; P = 0.006; Figure 3D ). For patients > 60 years old, the estimated five year DFS rates were 34.2% in the surgery alone group and 54.4% in the adjuvant SOX group, with an HR of 0.557 (95%CI: 0.3530.879; P = 0.011; Figure 3E ). The estimated fiveyear OS rates were 36.0% in the surgery alone group and 58.0% in the adjuvant SOX group, with an HR of 0.559 (95%CI: 0.3480.897; P = 0.015; Figure 3F ).
Evaluation of prognostic factors
The multivariate Cox proportional hazards model showed that age (HR, 1.629; 95%CI: 1.1552.297; P = 0.005), pTNM stage Ⅲ (HR = 10.258; 95%CI: 2.20247.783; P = 0.003), perineural invasion (HR = 1.637; 95%CI: 1.0562.538; P = 0.028), and SOX adjuvant chemotherapy (HR = 0.481; 95%CI: 0.3290.702; P < 0.001) were the independent prognostic factors for OS of GC patients after D2 gastrectomy (Table 3) .
Safety of adjuvant SOX chemotherapy
Out of 124 patients who received SOX adjuvant chemotherapy, 122 patients (98.4%) developed different grades of adverse events. Table 4 shows all the grades of adverse events reported by ≥ 10% of patients. Grade 3 or 4 adverse events were reported by 47 (37.9%) patients, and the most common adverse events were neutropenia (22.6%), leukopenia (8.9%) and thrombocytopenia (5.6%). Among all grades of adverse events, neutropenia (75.0%), leukopenia (60.5%) and peripheral sensory neuropathy (52.4%) had the highest event rate. In addition, one patient developed febrile neutropenia during the chemotherapy period. Fiftysix patients (45.2%) experienced reduction of S1 or/and oxaliplatin dose mainly because of the adverse events of neutropenia, leukopenia and peripheral sensory neuropathy. Seventyeight patients (62.9%) had a delay in the subsequent treatment and the most common reason is the adverse event of neutropenia.
Efficacy between SOX regimen and XELOX regimen
In adjuvant SOX group (57 patients), patients received 250 cycles chemotherapy in total with median cycles of 4. In adjuvant XELOX group (57 patients), patients received 258 cycles chemotherapy in total with median cycles of 5. After a median followup of 42 mo after gastrectomy, 47 patients developed relapse (21 in the SOX group and 26 in the XELOX group), 42 patients died (18 in the SOX group and 24 in the XELOX group). The estimated five-year DFS was 63.1% in the adjuvant SOX group and 54.0% in the adjuvant XELOX group (HR = 0.658; 95%CI: 0.3601.203; P = 0.340; Figure 4A ). The estimated five-year OS was 67.0% in the adjuvant SOX group and 56.5% in the adjuvant XELOX group (HR = 0.714; 95%CI: 0.3821.334; P = 0.361; Figure 4B ).
DISCUSSION
To the best of our knowledge, this was the first study to report that adjuvant chemotherapy with SOX can significantly improve the long-term survival of patients with GC after D2 radical gastrectomy, compared with surgery alone. After adjustment for confounders in 
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Ren DF et al . Adjuvant S-1 plus oxaliplatin for GC the propensity scorematched analysis, adjuvant chemotherapy with SOX, compared with surgery alone, improved the estimated five-year DFS and OS by approximately 12.9% (P = 0.001) and 22.5% (P < 0.001), respectively, with mild and welltolerated toxicities. The results were similar in the sensitivity analysis after addition of comorbidity to the propensity score model; the estimated fiveyear DFS and OS improved by 13.9% (P = 0.001) and 22.2% (P < 0.001), respectively. Moreover, our research showed that SOX regimen was as effective as XELOX for stage ⅠBⅢC GC patients after D2 dissection. These results strongly suggest that SOX is very likely to become a novel adjuvant chemotherapy regimen in patients with GC after D2 radical resection. D2 gastrectomy is the standard of surgical pro cedure in patients with GC in East Asia [12, 13] . Moreover, the European and United States treatment guidelines have suggested such procedure in resectable patients, based on the Dutch D1D2 clinical study, which showed that D2 gastrectomy reduced the number of cancer related deaths compared with D1 [46, 14, 15] . Two recent, excellent, and largescale randomized trials have shown that adjuvant chemotherapy can improve both DFS and OS in patients with resectable GC after D2 gastrectomy [7, 8] . The ACTSGC trial revealed that one year of ad juvant chemotherapy with S1 for stage Ⅱ/Ⅲ GC patients after D2 dissection increased the fiveyear RFS and OS rates from 53.1% to 65.4% and 61.1% to 71.7%, respectively [7] . The phase 3 CLASSIC study reported that six months of adjuvant chemotherapy with capecitabine and oxaliplatin after curative D2 gastrectomy in stage Ⅱ to ⅢB GC patients improved the estimated fiveyear DFS and OS rates from 53% to 68% and 69% to 78%, respectively [8] .
However, it should be noted that in the ACTSGC study, the effect of adjuvant chemotherapy with S1 in GC was stagedependent. In particular, a superior treatment effect was observed in stage Ⅱ cases (HR = 0.509), but it was rather ineffective for stage ⅢA (HR = 0.708) and stage ⅢB (HR = 0.791) disease [7] . These results suggested that S1 treatment was insufficient in eliminating micrometastatic cancer cells in cases with high pTNM stage. Furthermore, in their subgroup analysis, S1 treatment was shown to be not beneficial in elderly patients (≥ 60 years) and could not be sustained up to one year, with a 12mo completion rate of only 65.8% [16] . In the CLASSIC study, only 67% received the planned eight cycles of adjuvant capecitabine and oxaliplatin chemotherapy; 56% experienced grade 3 or 4 adverse events; and 90% needed dose modifications because of adverse events [17] . Therefore, novel adjuvant chemotherapy regimen with high efficiency and mild side effect needs to be explored for GC patients undergoing D2 dissection.
In this study, patients who received adjuvant che motherapy with SOX had significantly better survival than those who underwent surgery alone. In the ACTS GC trial and CLASSIC studies, both S1 monotherapy and oxaliplatin combined with capecitabine were confirmed to have a survival benefit for patients with GC after D2 dissection [7, 8] . Moreover, SOX was shown to have a high response rate (55.7%) and disease control rate (85.2%) in advanced GC [18] . Therefore, adjuvant chemotherapy with SOX is reasonable for GC. A singlearm, phase 2 study revealed that adjuvant SOX treatment was manageable and safe with optimal dose reduction or delay in the initiation of a subsequent cycle in stage Ⅲ GC patients undergoing D2 or more extensive lymphadenectomy [10] . Most recently, Wang et al [19] reported DFS (75.9%) and OS (85.2%) for 3 years by adjuvant SOX chemotherapy for Chinese patients in GC. However, there had been no study that evaluated the survival benefit of adjuvant SOX chemotherapy over surgery alone in GC patients after D2 gastrectomy. In this study, the survival rates of propensity score matched patients were compared between adjuvant SOX chemotherapy and surgery alone, adjuvant SOX and XELOX chemotherapy. The results showed that compared with surgery alone, adjuvant SOX chemotherapy had survival benefit in terms of DFS and OS. The 12.9% estimated five-year DFS benefit rate in this study was almost similar to the results of the ACTS GC trial and CLASSIC studies. In this present study, the 22.5% significant improvement in the estimated fiveyear OS with SOX regimen was probably related to the adjuvant chemotherapy itself and to the fact that some patients with relapse in the surgery alone group declined further antineoplastic therapy, whereas the patients in the adjuvant chemotherapy group remained to receive palliative therapy after relapse or due to more other comorbidities or competing causes of death in surgery alone patients. Our exploratory subgroup analysis showed the same survival benefits of adjuvant SOX chemotherapy in stage Ⅲ and elderly patients.
These results were similar to those of the CLASSIC study, but were not consistent with those of the ACTS GC clinical trial. These differences might suggest that adjuvant chemotherapy with a doublet regimen containing S1 was superior to monotherapy with S1 in these patients.
In this study, the adverse events documented with SOX were similar with the reported safety profiles of SOX in a phase 2 adjuvant therapy study and a phase 3 palliative treatment study on GC [10, 18] . The most common adverse events were neutropenia, leukopenia, nausea, peripheral sensory neuropathy, and mild elevation of hepatic transaminases. Overall, the frequency of adverse events ≥ grade 3 was less than 40%, suggesting that adjuvant SOX chemotherapy for GC after D2 radical gastrectomy was well tolerated. The present study had several limitations. First, the baseline characteristics of the patients were different between both groups. Although we performed propensity scorematched analysis and multivariate regression to reduce biases, remnant heterogeneity between groups cannot be excluded. Second, although the entire study population was relatively large, the sample size of patients receiving adjuvant SOX or XELOX chemotherapy was not adequate for subgroup analyses according to each variable. Third, a majority of GC patients after D2 dissection in China were stage Ⅲ disease which can't benefit from S-1 monotherapy according to ACTSGC trial; most of the patients in our study didn't receive S1 monotherapy. We didn't analyze data about patients only receiving S1 in our study. Forth, the definite relapse locations were not clear for part of the patients in our study, we didn't analyse the data about site of first relapse between patients received SOX or XELOX chemotherapy and those underwent surgery alone. Fifth, considering this study comprised Chinese patients, the dose of adjuvant SOX in other populations, especially Caucasians, remains to be further investigated because of the differences in the pharmacokinetics and toxicities of S1 between Caucasian and Asian patients [20] . Moreover, the role of SOX in patients undergoing D1 dissection needs to be confirmed.
In conclusion, compared with surgery alone, ad juvant SOX regimen significantly improved the long term survival of Chinese patients with stage ⅠBⅢC GC after D2 radical gastrectomy, with accepted side effects. It showed the similar DFS and OS outcomes with XELOX regimen which had become the standard adjuvant therapy nowadays. Therefore, SOX is likely to become a novel adjuvant chemotherapy regimen in GC. Several ongoing studies on the role of SOX for adjuvant chemotherapy in GC are expected to convey new and definite proofs in future [2124] . Ren DF et al . Adjuvant S-1 plus oxaliplatin for GC
